UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM SD

 

 

SPECIALIZED DISCLOSURE REPORT



 

 

GLOBUS MEDICAL, INC.

(Exact name of registrant as specified in charter)

 

 

 



2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403

(Address of principal executive offices) (Zip Code)



KEITH PFEIL

Executive Vice President, Chief Financial Officer and Chief Operating Officer, Chief Accounting Officer

(610) 930-1800

(Name and telephone number, including area code, of the person to contact in connection with this report.)





Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

 



 

---

 

Section 1 - Conflict Minerals Disclosure



Item 1.01 Conflict Minerals Disclosure and Report



Globus Medical, Inc. (the “Company”) is filing this Specialized Disclosure Report (“Form SD”), including the Conflict Minerals Report attached as Exhibit 1.01 hereto, for the calendar year ended December 31, 2023 to comply with Rule 13p-1 of the Securities Exchange Act of 1934, as amended. 



A copy of the Company’s Conflict Minerals Disclosure is publicly available at www.investors.globusmedical.com/investors-overview.



Item 1.02 Exhibit



The Company’s Conflict Minerals Report for calendar year 2023 is filed as Exhibit 1.01 to this Form SD and is incorporated herein by reference.



Section 2 – Exhibits



Item 2.01 Exhibits



See the Exhibit Index below, which is incorporated by reference herein.



---

 

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.



 

---

Exhibit 1.01

Globus Medical, Inc.
Conflict Minerals Report
for the Year Ended December 31, 2023



This Conflict Minerals Report (this “Report”) of Globus Medical, Inc.  (together with its subsidiaries, the “Company”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2023 to December 31, 2023.



Rule 13p-1 requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified in Rule 13p-1 are necessary to the functionality or production of those products. The specified minerals at this time are columbite-tantalite (coltan), cassiterite, gold, and wolframite, including their derivatives, which are limited to tantalum, tin, and tungsten (the “Covered Minerals”). The “Covered Countries” for the purposes of Rule 13p-1 and this Report are the Democratic Republic of the Congo and countries that share an internationally recognized border with the Democratic Republic of the Congo (the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia and Angola).



Overview



Globus Medical, Inc., together with its majority-owned or controlled subsidiaries, is a medical device company that develops and commercializes healthcare solutions with a mission to improve the quality of life of patients with musculoskeletal disorders. The Company primarily focuses on implants that promote healing in patients with musculoskeletal disorders, including the use of a robotic guidance and navigation system and products to treat patients who have experienced orthopedic traumas. The Company is an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures to assist surgeons in effectively treating their patients and to address new treatment options.  We offer a comprehensive portfolio of numerous innovative and differentiated technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Headquartered in Audubon, Pennsylvania, the Company markets and sells products through an exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia.



Description of Reasonable Country of Origin Inquiry



The Company has designed and conducted in good faith a  reasonable country of origin inquiry to determine whether any known products manufactured or contracted to be manufactured by the Company containing Covered Minerals originated in a Covered Country or whether they are from recycled or scrap sources. The Company designed its reasonable country of origin inquiry based on the due diligence framework set forth in the Organisation for Economic Co-operation and Development’s Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas. The Company’s reasonable country of origin inquiry is described below.



Governance and Management Systems



The Company maintains standards for its suppliers, which are set forth in its Purchase Order Terms and Conditions (the “P.O. Terms”) and can be found at https://www.globusmedical.com/about/po-terms-and-conditions/. The P.O. Terms require each of the Company’s suppliers to represent and warrant that it is in full compliance with all laws regarding the sourcing of minerals and to report to the Company the sources of products sold to the Company that contain Covered Minerals.



In conducting its good faith reasonable country of origin inquiry, the Company designated three Company contacts to identify suppliers who supply to the Company products that contain Covered Minerals, and to coordinate and communicate with those suppliers, as discussed below. The Company also has an internal management and record-keeping repository for its Covered Minerals inquiries to facilitate the review and assessment of the supplier responses.

---

 

Risk Assessment



The Company’s preliminary risk assessment included a survey of purchased raw materials and contract manufacturing arrangements to identify materials and products manufactured or contracted to be manufactured by the Company with a risk of containing Covered Minerals that are necessary to their functionality. After identifying the categories of products that might contain Covered Minerals that are necessary to their functionality, the Company sent questionnaires to the suppliers in those product categories with the following requests:





During the supplier survey period, the Company sent reminder notifications to non-responsive suppliers. The Company reviewed the responses to the questionnaires, as well as other information it received from suppliers regarding their due diligence efforts to identify the countries of origin of any Covered Minerals.



Results of Good Faith Reasonable Country of Origin Inquiry and Due Diligence



All supplier responses received were reviewed and, where the information provided by the supplier appeared to be outdated, incomplete or incorrect, follow-up inquiries were made in an effort to obtain current, complete, and accurate information.



Based on the supplier responses received to date as well as additional information obtained through our inquiries,  we note the following:





We intend to continue to engage with our suppliers to obtain current, complete, and accurate information about the supply chain.    



This Report has not been subjected to an independent private sector audit because such an audit was not required.



Risk Mitigation/Future Due Diligence Measures



The Company intends to continue to comply with Rule 13p-1 on an annual basis and expand or narrow the scope of future due diligence measures in light of any changes to the interpretations of Rule 13p-1 or changes in products or raw materials with a risk of containing Covered Minerals that are necessary to their functionality. The Company will review the adequacy of its due diligence measures to assess the source and chain of custody and work with its suppliers to increase the transparency of their supply chain. In this regard, the Company expects to continue to engage with its suppliers to obtain current, accurate and complete information about their supply chain and to evaluate the Company’s due diligence measures to identify more efficient and effective means to obtain current, accurate and complete information about its supply chain.



Availability of Report



The information contained in this report is publicly available at www.investors.globusmedical.com/investors-overview.



---

 

Cautionary Statement on Forward-Looking Statements



This Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements relating to the Company's intention to improve upon its supply chain due diligence efforts and risk mitigation efforts. These forward-looking statements are only predictions and are subject to risks, uncertainties and other factors, including, among other matters, the Company’s suppliers’ responsiveness and cooperation with the Company’s due diligence efforts and the accuracy of the information provided by the Company’s suppliers, the Company’s ability to identify and mitigate risks in its supply chain, whether smelters and refiners and other market participants responsibly source Covered Minerals, and political and regulatory developments, whether in the Covered Countries, the United States or elsewhere. The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

---